Personalized Drug Response in Ovarian Cancer
Consorcio Tecnologico en Biomedicinaclinico-molecular S. A.
Mauricio Bulnes Bulnes Carrasco
MetadatosMostrar el registro completo del ítem
Personalized drug response in ovarian cancer. This project aims to apply new approaches to deliver a chemosensitivity assay service which will predict which chemotherapy will and will not be beneficial to the individual cancer patient. This is neither a new assay nor concept. The rational has been in use since the 1980s but what we have changed is the nature of the cancer cells used in the assay the methodology and the concentrations of chemotherapeutic drugs. Our results to date show a 90% correlation with clinical outcome and an excellent distinction in terms of progression free survival. This service will improve the quality of life cost and progression free survival of the cancer patient. The exact methodology and drug concentration will be maintained as an industrial secret. The aim is to first establish the service in Chile then South America then globally. The assay in its first version will be focused on patients with ovarian cancer however we predict that the assay can be amplified to all liquid cancers i.e patients that present with fluid in the peritoneal cavity (ascitis) or in the lungs (pleural cavity).